Evidence map›Paper›PMID 40635989›Full record

ReviewReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025

New approaches to overcome radioresistance in glioblastoma: mechanisms, targets and role of innovative therapies, new particles and non-photon radiotherapy in 2024. A systematic review.

Kamel Debbi, Gokoulakrichenane Loganadane, Nhuhanh To, Mohamed Aziz Cherif, Chahrazed Boukhobza, Hanan Rida, Noémie Grellier, Hamid Mammar, Yazid Belkacemi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Stem cells therapy molecular tracking - the special focus on nuclear medicine.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kamel Debbi *AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), France.
Gokoulakrichenane Loganadane *AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), France.
Nhuhanh ToAP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), France.
Mohamed Aziz CherifAP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), France.
Chahrazed BoukhobzaAP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), France.
Hanan RidaAP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), France.
Noémie GrellierAP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), France.
Hamid MammarDepartment of Radiation Oncology, Proton Therapy Centre, Curie Institute, Orsay, France.
Yazid BelkacemiAP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most prevalent and deadliest form of primary malignant brain tumor in adults. Radiation associated with chemotherapy following maximal feasible surgery is the standard of care. However, it remains an incurable disease with inexorable recurrence after multimodal therapy due to several factors including tumor aggressiveness with high degree of tumor cell infiltration into surrounding brain tissue, high proliferation, molecular heterogeneity and radioresistance. A better understanding of the tumor biology may allow development of new strategies to overcome treatment resistance. Overcoming radioresistance in GBM has been considered as a challenge for decades. In this systematic review we aim to summarize biologic pathways and mechanisms of therapeutic resistance involved in GBM and try to define some potential future therapeutic perspectives. The main mechanisms of radioresistance that we will discuss are hypoxia, the subpopulation of cancer stem cells in GBM, and the epidermal growth factor receptor (EGFR) expression. We will also focus on the potential role of innovative approaches, such as targeted therapy, nanoparticles and non-photon radiotherapy.

Indexed as

brain tumorsglioblastoma multiformemolecular pathwaysnanoparticlesproton therapyradioresistance

Identifiers

PMID40635989
PMCPMC12236808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.